source
- Kardigan targets $320 million IPO to fund three late-stage heart drugsKardigan, a biotech focused on cardiovascular therapies, announced plans for an initial public offering that aims to raise about $320 million. The proceeds are intended to support the development…
- FDA grants emergency use authorization for generic Nitenpyram tablets to treat New World screwworm in dogs and catsThe U.S. Food and Drug Administration has issued an Emergency Use Authorization for generic Nitenpyram tablets to treat New World screwworm infestations in dogs, puppies, cats and kittens that weig…